BRPI0508931A - ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico - Google Patents

ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico

Info

Publication number
BRPI0508931A
BRPI0508931A BRPI0508931-0A BRPI0508931A BRPI0508931A BR PI0508931 A BRPI0508931 A BR PI0508931A BR PI0508931 A BRPI0508931 A BR PI0508931A BR PI0508931 A BRPI0508931 A BR PI0508931A
Authority
BR
Brazil
Prior art keywords
nucleic acid
pharmaceutical composition
effective amount
modulators
coagulation
Prior art date
Application number
BRPI0508931-0A
Other languages
English (en)
Inventor
Christopher Rusconi
Original Assignee
Regado Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regado Biosciences Inc filed Critical Regado Biosciences Inc
Publication of BRPI0508931A publication Critical patent/BRPI0508931A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

CIDO NUCLEIDO ISOLADO, COMPOSIçãO FARMACêUTICA E USOS DE UMA QUANTIDADE EFICAZ DE UM PRIMEIRO LIGANTE DE áCIDO NUCLEICO A invenção proporciona ligantes de ácido nucleico aperfeiçoados que inibem a coagulação e moduladores aperfeiçoados de ácidos nucleicos para proporciona moduladores ideais de coagulação. Esses ácidos nucleicos e moduladores aperfeicoados são particularmente úteis para inibição da coagulação em um hospedeiro que está sofrendo um regime terapêutico, tal como cirurgia ou bypass da artéria coronária.
BRPI0508931-0A 2004-04-22 2005-04-22 ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico BRPI0508931A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56487304P 2004-04-22 2004-04-22
PCT/US2005/013926 WO2005106042A2 (en) 2004-04-22 2005-04-22 Improved modulators of coagulation factors

Publications (1)

Publication Number Publication Date
BRPI0508931A true BRPI0508931A (pt) 2007-08-14

Family

ID=35242272

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508931-0A BRPI0508931A (pt) 2004-04-22 2005-04-22 ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico

Country Status (16)

Country Link
US (7) US7304041B2 (pt)
EP (2) EP2460811A1 (pt)
JP (1) JP4718541B2 (pt)
KR (1) KR101185050B1 (pt)
CN (2) CN1980947B (pt)
AU (1) AU2005238490B2 (pt)
BR (1) BRPI0508931A (pt)
CA (1) CA2563176A1 (pt)
DK (1) DK1745062T3 (pt)
ES (1) ES2494940T3 (pt)
IL (1) IL178564A0 (pt)
PL (1) PL1745062T3 (pt)
PT (1) PT1745062E (pt)
SG (1) SG152262A1 (pt)
SI (1) SI1745062T1 (pt)
WO (1) WO2005106042A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026932A2 (en) 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
PT2070939E (pt) * 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
CN1980947B (zh) * 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
JP4833727B2 (ja) * 2006-05-08 2011-12-07 藤森工業株式会社 血管内皮細胞を用いた血栓観測方法および血栓観測装置
JP2009538325A (ja) * 2006-05-26 2009-11-05 リガド・バイオサイエンシーズ・インコーポレーテツド Ｒｅｇ１抗凝固系の投与
CA2682580A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
US20090163437A1 (en) * 2007-10-16 2009-06-25 Regado Biosciences, Inc. Steady-state subcutaneous administration of aptamers
CA2740785C (en) 2008-10-15 2017-06-20 Isis Pharmaceuticals, Inc. Modulation of factor 11 expression
EP2368124A4 (en) * 2008-11-24 2012-09-19 Bayer Healthcare Llc METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY
FR2942231B1 (fr) * 2009-02-19 2015-03-20 Lfb Biotechnologies Acides nucleiques se liant specifiquement au facteur vii/viia humain, et utilisations
RU2011146158A (ru) * 2009-04-15 2013-05-27 АйЭсАйЭс ФАРМАСЬЮТИКАЛЗ, ИНК. Модуляция воспалительных реакций фактором хi
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
US8889645B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
JP2012528597A (ja) * 2009-06-03 2012-11-15 レガド・バイオサイエンシズ・インク 血小板グリコプロテインｖｉの核酸調節因子
US8889646B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
IN2012DN02345A (pt) 2009-09-16 2015-08-21 Univ Duke
WO2011059459A1 (en) * 2009-11-16 2011-05-19 Regado Biosciences, Inc Physical characterization of oligonucleotides conjugates
US20110117660A1 (en) * 2009-11-16 2011-05-19 Brooks Douglas G Physical characterization of oligonucleotide conjugates
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
AU2012249658A1 (en) * 2011-04-26 2013-05-09 Regado Biosciences, Inc. A method for manufacturing pegylated oligonucleotides
US8962553B2 (en) 2011-11-17 2015-02-24 Cebix Ab Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
WO2014066084A1 (en) * 2012-10-24 2014-05-01 Novamedica Limited Liability Company Nucleic acid modulators of alpha2beta1
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
FR3011250A1 (fr) * 2013-09-30 2015-04-03 Lab Francais Du Fractionnement Acides nucleiques se liant specifiquement au facteur ix/ixa humain, et utilisations
US9545383B2 (en) 2014-04-01 2017-01-17 Massachusetts Institute Of Technology Blood clotting control
WO2015161094A1 (en) 2014-04-16 2015-10-22 Duke University Electrospun cationic nanofibers and methods of making and using the same
WO2016176426A1 (en) 2015-04-28 2016-11-03 Duke University Thrombus imaging aptamers and methods of using same
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US12514872B2 (en) 2015-11-04 2026-01-06 Duke University Polycationic polymers for use in treating and detecting cancer
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3512526A4 (en) 2016-09-16 2020-05-27 Duke University VON WILLEBRAND FACTOR (VWF) TARGETING AGENTS AND METHODS OF USE
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
WO2018098328A1 (en) 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2019213150A1 (en) 2018-04-30 2019-11-07 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
WO2019217397A2 (en) * 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for improving strand biased
IL277970B2 (en) 2018-05-09 2025-03-01 Ionis Pharmaceuticals Inc Oligomeric compounds comprising modified oligonucleotides and conjugated groups for use in the treatment of end-stage renal disease, chronic kidney disease and coronary artery disease
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
CN111019100B (zh) * 2018-10-10 2022-05-03 中国石油化工股份有限公司 一种蒙脱土改性的阻隔聚酯及其制备方法
US12553054B2 (en) 2018-10-26 2026-02-17 North Carolina State University Compositions and methods related to nucleic acid anticoagulants
CN113646323A (zh) 2019-03-29 2021-11-12 日油株式会社 分支型分解性聚乙二醇键合物
CN110305868B (zh) * 2019-07-03 2022-08-02 合肥工业大学 凝血酶环状核酸适配体及其应用
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4069363A4 (en) * 2019-12-04 2024-08-28 Duke University METHODS FOR CONTROLLING COAGULATION IN EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
US20240226307A9 (en) 2021-02-22 2024-07-11 Duke University Non-immunogenic poegma-aptamer conjugates

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
DE3587814T2 (de) * 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
FR2628111B1 (fr) * 1988-03-03 1992-01-24 Rhone Poulenc Chimie Polymeres a groupements imides faits a partir de diamines encombrees et leurs procedes de preparation
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5670633A (en) * 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5872232A (en) * 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
IL101038A0 (en) 1991-02-21 1992-11-15 Gilead Sciences Inc Agent specific for trombin and its use
US5840867A (en) * 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
AU2580892A (en) 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
EP0637965B1 (en) * 1991-11-26 2002-10-16 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5792608A (en) * 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5817781A (en) * 1992-06-01 1998-10-06 Gilead Sciences, Inc. Modified internucleoside linkages (II)
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
AU5162993A (en) 1992-09-23 1994-04-12 Integrated Dna Technologies, Inc. Siloxy oligonucleotide analogs
DK0593901T3 (da) 1992-09-24 1997-10-27 Hoechst Ag Oligoribonucleotid- og ribozym-analoge med terminale 3-3- og 5-5-bindinger.
ATE315101T1 (de) 1992-09-29 2006-02-15 Gilead Sciences Inc Nukleinsäureliganden und ihre herstellungsmethoden
US5534408A (en) * 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
WO1994009792A1 (en) 1992-10-23 1994-05-11 University Of Massachusetts Medical Center Small molecule inhibition of rna/ligand binding
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
ATE174600T1 (de) * 1993-10-27 1999-01-15 Ribozyme Pharm Inc 2'-amido-und 2'-peptido-modifizierte oligonukleotide
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5891689A (en) * 1994-04-12 1999-04-06 Innovir Laboratories, Inc. Heme-bearing microparticles for targeted delivery of drugs
US5882941A (en) * 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
ES2210306T3 (es) * 1994-07-20 2004-07-01 The General Hospital Corporation Sistemas de trampa para interacciones, para detectar interacciones de proteinas.
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5659023A (en) * 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
DE69636160D1 (de) 1995-03-06 2006-06-29 Isis Pharmaceuticals Inc Verfahren zur synthese von 2'-0-substituierten pyrimidinen und oligomere davon
US6001820A (en) 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6117557A (en) * 1995-04-19 2000-09-12 Lexmark International, Inc. Caprolactone ester polyurethane developer roller
US5780221A (en) * 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
US6183967B1 (en) * 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
JP3706186B2 (ja) * 1995-12-25 2005-10-12 日本トムソン株式会社 直動転がり案内ユニット装置
WO1997042317A1 (en) 1996-05-07 1997-11-13 T Cell Sciences, Inc. APTAMERS FOR COMPLEMENT PROTEIN C3b
US5839443A (en) * 1996-05-16 1998-11-24 The Trustees Of Columbia University In The City Of New York Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US5792613A (en) * 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US5779917A (en) * 1996-08-09 1998-07-14 Fluid Technologies, Inc. Process for separating fluids having different densities
DE19637418A1 (de) * 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Homogene Nachweisverfahren zur Bestimmung von Subpopulationen eines Analyten
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
US6316403B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
AU5821998A (en) * 1997-01-13 1998-08-03 Scripps Research Institute, The Nucleic acid binders having an hydroxyamine motif
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6150461A (en) 1997-05-27 2000-11-21 Hisamitsu Pharmaceutical Co., Inc. Carriers targettable to organ
CA2304813A1 (en) * 1997-09-22 1999-04-08 Fritz Eckstein Nucleic acid catalysts with endonuclease activity
JP3143740B2 (ja) 1997-10-29 2001-03-07 工業技術院長 ＨＩＶのＴａｔタンパク質に高い親和性を持つＲＮＡ
US6054274A (en) * 1997-11-12 2000-04-25 Hewlett-Packard Company Method of amplifying the signal of target nucleic acid sequence analyte
US5989823A (en) * 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
AU2018999A (en) 1997-12-31 1999-07-19 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
US5882870A (en) * 1998-01-14 1999-03-16 Becton Dickinson And Company Rapidly reversed thrombin binding oligonucleotide anticoagulants
WO1999050462A1 (en) 1998-03-27 1999-10-07 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)
US6180348B1 (en) * 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US6163174A (en) * 1998-05-26 2000-12-19 The University Of Rochester Digital buffer circuits
GB9814506D0 (en) * 1998-07-03 1998-09-02 Stanley Christopher J Optical sensor for insitu measurement of analytes
US6995249B1 (en) 1998-08-14 2006-02-07 Japan Science And Technology Corporation Nucleic acid capable of binding specifically to Ras target protein
AU2342900A (en) * 1998-09-23 2000-05-01 Cleveland Clinic Foundation, The Novel interferon stimulated and repressed genes
WO2000020040A1 (en) 1998-10-08 2000-04-13 University Of Massachusetts Controlling gene expression in living cells
AU6298899A (en) 1998-10-09 2000-05-01 Ingene, Inc. Production of ssdna (in vivo)
AU6522599A (en) 1998-10-23 2000-05-15 Children's Medical Center Corporation Use of a self-cleaving rna motif to modulate gene expression
US6114038A (en) * 1998-11-10 2000-09-05 Biocrystal Ltd. Functionalized nanocrystals and their use in detection systems
US6051388A (en) * 1998-12-22 2000-04-18 Toxin Alert, Inc. Method and apparatus for selective biological material detection
DE19901008A1 (de) 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HPV E6-Proteinen
DE19901009A1 (de) 1999-01-13 2000-07-20 Deutsches Krebsforsch Peptide zur Inhibierung von HBV-Core-Proteinen
US6329145B1 (en) * 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6110462A (en) * 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
DE60045706D1 (de) * 1999-03-18 2011-04-21 Exiqon As Detektion von genmutationen mittels lna primer
US6171795B1 (en) * 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
AU2001250572A1 (en) * 2000-04-07 2001-10-23 Epigenomics Ag Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
US6258601B1 (en) * 2000-09-07 2001-07-10 Isis Pharmaceuticals, Inc. Antisense modulation of ubiquitin protein ligase expression
WO2002026932A2 (en) * 2000-09-26 2002-04-04 Duke University Rna aptamers and methods for identifying the same
PT2070939E (pt) * 2001-05-25 2014-06-09 Univ Duke Moduladores de agentes farmacológicos
CN100412090C (zh) 2002-05-01 2008-08-20 舍林股份公司 作为抗凝剂的新的靶向组织因子的血栓调节蛋白融合蛋白
ATE516366T1 (de) 2002-07-25 2011-07-15 Archemix Corp Regulierte aptamer-therapeutika
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
AU2003273096A1 (en) 2002-10-22 2004-05-13 Korea Research Institute Of Chemical Technology Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
AU2003294437A1 (en) 2002-11-21 2004-06-18 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
WO2004050899A2 (en) 2002-12-03 2004-06-17 Archemix Corporation Method for in vitro selection of 2’-substituted nucleic acids
US20050037394A1 (en) 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
WO2005052121A2 (en) 2003-11-21 2005-06-09 Archemix Corp. Multivalent aptamers
EP1732571A4 (en) 2004-03-05 2009-09-09 Archemix Corp CONTROLLED MODULATION OF PHARMACOKINETICS AND BIODISTRIBUTION OF APTAMER THERAPEUTICS
WO2005111238A2 (en) 2004-04-19 2005-11-24 Archemix Corporation Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
CN1980947B (zh) * 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry

Also Published As

Publication number Publication date
US8389489B2 (en) 2013-03-05
KR20070031907A (ko) 2007-03-20
CN103045601B (zh) 2015-04-01
CA2563176A1 (en) 2005-11-10
AU2005238490A1 (en) 2005-11-10
AU2005238490B2 (en) 2010-11-18
JP4718541B2 (ja) 2011-07-06
US20080125383A1 (en) 2008-05-29
US20060040881A1 (en) 2006-02-23
US8859518B2 (en) 2014-10-14
US7531524B2 (en) 2009-05-12
US20100197900A1 (en) 2010-08-05
PT1745062E (pt) 2014-07-11
US20070105809A1 (en) 2007-05-10
US20080153769A1 (en) 2008-06-26
US20130197065A1 (en) 2013-08-01
WO2005106042A3 (en) 2006-12-07
ES2494940T3 (es) 2014-09-16
US7304041B2 (en) 2007-12-04
EP1745062A4 (en) 2008-04-23
EP1745062B1 (en) 2014-06-04
DK1745062T3 (da) 2014-08-11
CN1980947B (zh) 2013-01-30
PL1745062T3 (pl) 2014-10-31
EP2460811A1 (en) 2012-06-06
US7723315B2 (en) 2010-05-25
IL178564A0 (en) 2007-02-11
KR101185050B1 (ko) 2012-10-04
CN103045601A (zh) 2013-04-17
WO2005106042A2 (en) 2005-11-10
CN1980947A (zh) 2007-06-13
EP1745062A2 (en) 2007-01-24
JP2007534324A (ja) 2007-11-29
SI1745062T1 (sl) 2014-09-30
SG152262A1 (en) 2009-05-29
US20150247147A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
SG152262A1 (en) Improved modulators of coagulation factors
BR112021019722A2 (pt) Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
CO6761351A2 (es) Polipéptidos que se enlazan a cxcr2
BRPI0721137B8 (pt) compostos para modulação de atividade de c-fms e/ou kit, composição, kit e uso dos referidos compostos.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0511479A (pt) molécula de ligação tendo atividade neutralizadora do vìrus da raiva, variante funcional de uma molécula de ligação, imunoconjugado, molécula de ácido nucléico, vetor, hospedeiro, método para produzir uma molécula de ligação ou uma variante funcional, composição farmacêutica, uso de uma molécula de ligação, uma variante funcional, um imunoconjugado como, ou uma composição, kit, método para identificar uma molécula de ligação ou uma molécula de ácido nucléico, e, coleção de moléculas de ligação humanas na superfìcie de pacotes genéticos replicáveis
BR112012010766A2 (pt) composições e métodos de tratamento da colite e de outras doenças instestinais
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BRPI0418251C1 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BR112014027697A2 (pt) polipeptídeos que se ligam ao receptor de quimiocina
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
BRPI0611620A2 (pt) mimÉticos de glicocorticàide, mÉtodos de fazÊ-los, composiÇÕes farmacÊuticas e usos dos mesmos
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
ATE502038T1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
AR066395A1 (es) Reovirus que tienen secuencias modificadas
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]